$ONC

Lee Chan Henry sold $157K of ONC

Lee Chan Henry (SVP, General Counsel) sold 590 shares of BeOne Medicines Ltd. (ONC) at $265.98 ($0.16M total) on 2026-06-16.

Original reporting
SEC EDGAR · Lee Chan Henry
Published Jun 18, 2026, 9:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount, date, and post-transaction holdings (0 shares).

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not change fundamentals or provide new operational/financial guidance.

03

What to watch

No 10b5-1 plan is stated, but the article also provides no context on prior grants, vesting schedules, or whether other insiders/funds are trading—so signal-to-noise is low.

Relevance 4/10Novelty 5/10Timing: after-hours/filing update on 2026-06-18 (SEC EDGAR Form 4)

Background

This is an SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

SEC Form 4 shows ONC’s SVP & General Counsel Lee Chan Henry sold 590 shares on 2026-06-16 for $156,925.25.

Expected impact

Likely limited near-term impact; any reaction should be small and short-lived unless followed by additional insider activity or company-specific news.

Evidence & confidence

The filing is primary-source and specific, but the transaction is a relatively small, single insider sale with no accompanying company event or guidance change in the text.

Market effects

Minimal; this is company-specific insider trading with no sector-wide regulatory/clinical/financing signal in the text.

None indicated.

None indicated.

Counterpoint

The sale could be purely liquidity/tax-driven and not predictive, especially since the filing does not cite any adverse company development.

Key entities

  • BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction disclosure (ONC).

  • Lee Chan Henry

    SVP, General Counsel; sold 590 shares on 2026-06-16.

Related articles

$ONCHigh

BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$ONCMed

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

Citizens kept a “Market Outperform” rating and $396 price target on BeOne Medicines (NASDAQ:ONC) after the company presented tumor clinical data at ASCO 2026. Citizens highlighted three pipeline programs: BGB-43395 (HR+/HER2- metastatic breast cancer), BG-C9074 (ovarian cancer maintenance), and BGB-B2033 (liver cancer). The target was based on discounted earnings and revenue multiples, with Citizens citing $4.85 billion cash and 88% gross margins.